PDGF-BB induces cyclin A expression and CDK2 activity in NFAT-dependent
manner in VSMC. A, quiescent VSMC were treated with and without
PDGF-BB (20 ng/ml) for the indicated times, and cell extracts were prepared.
An equal amount of protein from control and each treatment was analyzed either
for cyclin A and CDK2 levels by Western blotting or for CDK2 activity by
immunocomplex kinase assay. B, quiescent VSMC were treated with and
without PDGF-BB (20 ng/ml) in the presence and absence of CsA (10
μm) for the indicated times, and cell extracts were prepared and
analyzed for cyclin A and CDK2 levels and/or activity as described in A.
C, all the conditions were the same as in B except that cells
were transduced with either Ad-GFP (control) or Ad-VIVIT with an m.o.i. of 80
and quiesced before treatment with and without PDGF-BB (20 ng/ml) and analyzed
for cyclin A and CDK2 levels and/or activity. The bar graphs
represent mean ± S.D. values of three independent experiments.
*, p < 0.01 versus control or GFP; †,
p < 0.01 versus PDGF-BB or GFP + PDGF-BB treatment
alone.